PolyPid Ltd. (PYPD)
| Market Cap | 35.36M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -30.84M |
| Shares Out | 10.19M |
| EPS (ttm) | -4.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 71,013 |
| Open | 3.420 |
| Previous Close | 3.500 |
| Day's Range | 3.410 - 3.510 |
| 52-Week Range | 2.300 - 4.420 |
| Beta | 1.33 |
| Analysts | Strong Buy |
| Price Target | 11.40 (+228.53%) |
| Earnings Date | Aug 13, 2025 |
About PYPD
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumo... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for PYPD stock is "Strong Buy." The 12-month stock price target is $11.4, which is an increase of 228.53% from the latest price.
News
PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results
PETACH TIKVA, Israel, June 17, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced t...
PESG Research Update: PolyPid's SHIELD II Trial Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention
PESG issues a new briefing following PolyPid's clinical success; Revolutionary 58% Reduction in Surgical Site Infections Positions PolyPid's D-PLEX100 as Potential New Standard of Care in the Future P...
PESG Research Update: PolyPid SHIELD's II Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention
PESG issues a new briefing following PolyPid's clinical success; Revolutionary 58% Reduction in Surgical Site Infections Positions PolyPid's D-PLEX100 as Potential New Standard of Care in the Future P...
BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript
In a call hosted today, June 9, 2025, PolyPid Ltd. unveiled highly successful topline results from its SHIELD II Phase 3 trial of D-PLEX100 for preventing surgical site infections (SSIs) in abdominal ...
PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints
PETACH TIKVA, Israel, June 09, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced po...
PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025
PETACH TIKVA, Israel, June 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced t...
PESG Research Report: Revolutionary Surgical Infection Prevention: PolyPid's D-PLEX100 Approaches Critical Phase 3 Data Readout
New report from PESG Research brand covers PolyPid*, which is tackleing the $10 billion dollar a year surgeical site infections cost with its innovative PLEX technology New report from PESG Research b...
PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025
PETACH TIKVA, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, will participate in...
PolyPid Ltd. (PYPD) Q1 2025 Earnings Call Transcript
PolyPid Ltd. (NASDAQ:PYPD) Q1 2025 Earnings Call May 14, 2025 8:30 AM ET Company Participants Brian Ritchie - Investor Relations Dikla Czaczkes Akselbrad - Chief Executive Officer Jonny Missulawin - ...
PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results
PolyPid Successfully Completed Enrollment in Phase 3 SHIELD II Trial of D-PLEX100 , with Top-Line Results Anticipated in Current Quarter Company Continues to Advance Regulatory Submission Preparations...
PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025
PETACH TIKVA, Israel, April 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced t...
PolyPid to Participate in The Citizens Life Sciences Conference
PETACH TIKVA, Israel, April 22, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced ...
PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections
PETACH TIKVA, Israel, March 11, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced t...
PolyPid to Participate in the 37th Annual ROTH Conference
PETACH TIKVA, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced ...
PolyPid Ltd. (PYPD) Q4 2024 Earnings Call Transcript
PolyPid Ltd. (NASDAQ:PYPD) Q4 2024 Results Conference Call February 12, 2025 8:30 AM ET Company Participants Brian Ritchie - Investor Relations, LifeSci Advisors Dikla Czaczkes Akselbrad - Chief Exec...
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results
Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients SHIELD II Enroll ed more than 7 00 P atients to D ate; Enrollment Completion Expected in ...
PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
PETACH TIKVA, Israel, Jan. 30, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced t...
PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025
PETACH TIKVA, Israel, Jan. 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced th...
Kemper To Rally More Than 25%? Here Are 4 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million
• 630 Patients Enrolled To Date; Enrollment Completion Now Expected in Q1 2025 with Top-line Results Anticipated in Q2 2025;
PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy
PETACH TIKVA, Israel, Dec. 11, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced a ...
PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance
PETACH TIKVA, Israel, Nov. 29, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced th...
PolyPid Ltd. (PYPD) Q3 2024 Earnings Call Transcript
PolyPid Ltd. (NASDAQ:PYPD) Q3 2024 Earnings Conference Call November 13, 2024 8:30 AM ET Company Participants Brian Ritchie - Investor Relations, LifeSci Advisors Dikla Czaczkes Akselbrad - Chief Exe...
PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference
PETACH TIKVA, Israel, Nov. 07, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced t...
PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024
PETACH TIKVA, Israel, Oct. 30, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced th...